The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) and granted the in vivo CRISPR-Cas...

Some of the best links we picked up around the internet

Some of the best links we picked up around the internet

A single intravenous dose of Intellia Therapeutics’ in vivo CRISPR-Cas9 therapy lonvoguran ziclumeran (lonvo-z) reduced monthly hereditary angioedema...

Intellia Therapeutics has initiated a rolling biologics license application (BLA) with the U.S. Food and Drug Administration for lonvoguran ziclumeran...

Some of the best links we picked up around the internet

Some of the best links we picked up around the internet

Some of the best links we picked up around the internet